Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)
On February 6, 2024, Robert Gagnon, a director at Verastem Inc, executed a sale of 9,204 shares of the company. The transaction was filed with the SEC and can be found in the following SEC Filing.
Verastem Inc, traded under the ticker VSTM, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life for cancer patients. The company has a portfolio of product candidates designed to inhibit critical signaling pathways that promote cancer cell survival and proliferation.
Over the past year, the insider has sold a total of 24,961 shares and has not made any purchases of the company's stock. The recent sale by the insider is part of a broader trend observed over the past year, where there have been no insider buys and 23 insider sells for Verastem Inc.
On the date of the insider's recent transaction, shares of Verastem Inc were trading at $13.7 each, resulting in a market capitalization of $339.854 million for the company.
The stock's price-to-GF-Value ratio stood at 9.86, indicating that Verastem Inc was significantly overvalued according to the GF Value of $1.39. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is calculated based on historical trading multiples, an adjustment factor for past returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
